Clinical Perfusion Systems Market worth $1,198.8 Million by 2021
The growth of the market can be attributed to the initiatives by
governments & NGOs to encourage organ donation, increasing
investment in cell-based research, increasing prevalence of
cardiovascular & respiratory diseases, and developments in biologics
manufacturing. The high cost of organ transplantation and organ
supply-demand gap, however, are expected to hinder the growth of the
market.
According to research report the Clinical Perfusion Systems Market is projected to reach USD 1,198.8 million by 2021 from USD 989.4 million in 2016, at a CAGR of 3.9% from 2016 to 2021.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=164273069
North
America is estimated to account for the largest share of the global
Clinical Perfusion Systems Market, followed by Europe. The Asia-Pacific
region is expected to witness the highest growth in the market during
the forecast period. This growth will be particularly centered on China,
Japan, and India.
Perfusion systems are used to bypass
cardiopulmonary systems in order to treat patients with cardiac and
respiratory diseases surgically. Perfusion systems such as heart-lung
machines deliver oxygen and remove carbon dioxide in patients when the
heart and lungs fail to carry out the process of blood oxygenation. With
the increasing prevalence of cardiovascular and respiratory diseases
across the globe, the use of perfusion systems is expected to rise in
the coming years.
During this research study, major players
operating in the perfusion systems market in various regions have been
identified, and their offerings, and their have been analyzed through
in-depth discussions. Top-down and bottom-up approaches have been used
to determine the overall market size.
The perfusion systems
market is segmented on the basis of type (namely cardiopulmonary
perfusion systems, ex vivo organ perfusion systems, and cell perfusion
systems) and region.
By component, the cardiopulmonary perfusion
systems market is segmented into heart-lung machines, perfusion pumps,
oxygenators, monitoring systems, cannulas, and other components. The
oxygenators segment accounted for the largest share of the
cardiopulmonary perfusion systems market in 2016.
Based on
technique, the ex vivo organ perfusion systems market is segmented into
hypothermic machine perfusion and normothermic machine perfusion. The
hypothermic machine perfusion segment held the largest share of the ex
vivo organ perfusion systems market in 2016 and is also projected to
grow at the highest CAGR during the forecast period.
Get Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=164273069
The major players in the Clinical Perfusion Systems Market
include Getinge AB (Sweden), Medtronic plc (Ireland), LivaNova PLC
(U.K.), Terumo Corporation (Japan), and XENIOS AG (Germany). The major
players in the ex vivo organ perfusion system market are Lifeline
Scientific, Inc. (U.S.) and XVIVO Perfusion AB (Sweden), while, Repligen
Corporation (U.S.), Spectrum Laboratories, Inc. (U.S.), Merck KGaA
(Germany), Harvard Bioscience, Inc. (U.S.), and ALA Scientific
Instruments, Inc. (U.S.) are some of the leading players in the cell
perfusion systems market.
Comments
Post a Comment